A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder

Summary

The objective of this proof-of-concept study to evaluate mazdutide in participants with alcohol use disorder (AUD). For any individual participant, the maximum duration of study participation is approximately 36 weeks, including screening and posttreatment follow-up.

Timeline

Start

2025-02-06

Primary completion

2026-03-19

Completion

2026-05-19

Drugs

Indications